Suppr超能文献

两个相邻的细胞质酪氨酸残基在多药耐药相关蛋白1(ABCC1)转运活性及对磺脲类药物敏感性中的作用

Role of two adjacent cytoplasmic tyrosine residues in MRP1 (ABCC1) transport activity and sensitivity to sulfonylureas.

作者信息

Conseil Gwenaëlle, Deeley Roger G, Cole Susan P C

机构信息

Divison of Cancer Biology and Genetics, Cancer Research Institute, Queen's University, Kingston, Ont., K7L 3N6, Canada.

出版信息

Biochem Pharmacol. 2005 Feb 1;69(3):451-61. doi: 10.1016/j.bcp.2004.10.014. Epub 2004 Dec 16.

Abstract

The human ATP-binding cassette (ABC) protein MRP1 causes resistance to many anticancer drugs and is also a primary active transporter of conjugated metabolites and endogenous organic anions, including leukotriene C(4) (LTC(4)) and glutathione (GSH). The sulfonylurea receptors SUR1 and SUR2 are related ABC proteins with the same domain structure as MRP1, but serve as regulators of the K(+) channel Kir6.2. Despite their functional differences, the activity of both SUR1/2 and MRP1 can be blocked by glibenclamide, a sulfonylurea used to treat diabetes. Residues in the cytoplasmic loop connecting transmembrane helices 15 and 16 of the SUR proteins have been implicated as molecular determinants of their sensitivity to glibenclamide and other sulfonylureas. We have now investigated the effect of mutating Tyr(1189) and Tyr(1190) in the comparable region of MRP1 on its transport activity and sulfonylurea sensitivity. Ala and Ser substitutions of Tyr(1189) and Tyr(1190) caused a > or =50% decrease in the ability of MRP1 to transport different organic anions, and a decrease in LTC(4) photolabeling. Kinetic analyses showed the decrease in GSH transport was attributable primarily to a 10-fold increase in K(m). In contrast, mutations of these Tyr residues had no major effect on the catalytic activity of MRP1. Furthermore, the mutant proteins showed no substantial differences in their sensitivity to glibenclamide and tolbutamide. We conclude that MRP1 Tyr(1189) and Tyr(1190), unlike the corresponding residues in SUR1, are not involved in its differential sensitivity to sulfonylureas, but nevertheless, may be involved in the transport activity of MRP1, especially with respect to GSH.

摘要

人类ATP结合盒(ABC)蛋白MRP1可导致对多种抗癌药物产生耐药性,并且还是结合代谢物和内源性有机阴离子(包括白三烯C4(LTC4)和谷胱甘肽(GSH))的主要活性转运蛋白。磺脲类受体SUR1和SUR2是与MRP1具有相同结构域结构的相关ABC蛋白,但作为钾通道Kir6.2的调节剂。尽管它们功能不同,但SUR1/2和MRP1的活性均可被用于治疗糖尿病的磺脲类药物格列本脲阻断。SUR蛋白跨膜螺旋15和16之间的胞质环中的残基被认为是其对格列本脲和其他磺脲类药物敏感性的分子决定因素。我们现在研究了MRP1可比区域中Tyr(1189)和Tyr(1190)突变对其转运活性和磺脲类药物敏感性的影响。Tyr(1189)和Tyr(1190)被丙氨酸和丝氨酸取代后,MRP1转运不同有机阴离子的能力下降了≥50%,并且LTC4光标记减少。动力学分析表明,GSH转运的下降主要归因于米氏常数(Km)增加了10倍。相比之下,这些Tyr残基的突变对MRP1的催化活性没有重大影响。此外,突变蛋白对格列本脲和甲苯磺丁脲的敏感性没有实质性差异。我们得出结论,与SUR1中的相应残基不同,MRP1的Tyr(1189)和Tyr(1190)不参与其对磺脲类药物的差异敏感性,但可能参与MRP1的转运活性,尤其是与GSH相关的转运活性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验